Oramed Pharmaceuticals
ORMP
56 hedge funds and large institutions have $12.1M invested in Oramed Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 9 closing their positions.
162% more call options, than puts
Call options by funds: $136K | Put options by funds: $52K
101% more capital invested
Capital invested by funds: $5.99M → $12.1M (+$6.07M)
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
7.25% more ownership
Funds ownership: 5.7% → 12.95% (+7.2%)
0% more funds holding
Funds holding: 56 → 56 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$2.24M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$1.12M |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.03M |
| 4 |
Renaissance Technologies
New York
|
+$634K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$536K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$401K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$232K |
| 3 |
Citigroup
New York
|
-$108K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$71.2K |
| 5 |
VF
Virtu Financial
New York
|
-$45K |
ORMP Hedge Fund Activity: Q4 2023 in Review
56 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2023, worth a combined $12.1M — up 101% from $5.99M a quarter earlier.
Fund positioning in ORMP was balanced in Q4 2023: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 11 trimmed.
The largest buyer was Murchinson, opening a new position worth an estimated $2.24M. The largest seller was Goldman Sachs, exiting entirely with an estimated $401K sold.
- 56 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $12.1M of Oramed Pharmaceuticals stock for Q4 2023, up 101% quarter-over-quarter.
- 9 funds opened new Oramed Pharmaceuticals positions in Q4 2023 and 9 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2023 was Murchinson, an estimated $2.24M added.
- The largest Oramed Pharmaceuticals seller in Q4 2023 was Goldman Sachs, an estimated $401K sold.
Based on aggregated 13F filings for Q4 2023.